{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:20:43Z","timestamp":1783660843894,"version":"3.55.0"},"reference-count":57,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T00:00:00Z","timestamp":1445644800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>The use of cannabinoids for the treatment of chronic diseases has increased in the United States, with 23 states having legalized the use of marijuana. Although currently available cannabinoid compounds have shown effectiveness in relieving symptoms associated with numerous diseases, the use of cannabis or cannabinoids is still controversial mostly due to their psychotropic effects (e.g., euphoria, laughter) or central nervous system (<jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>)\u2010related undesired effects (e.g., tolerance, dependence). A potential strategy to use cannabinoids for medical conditions without inducing psychotropic or <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>\u2010related undesired effects is to avoid their actions in the <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>. This approach could be beneficial for conditions with prominent peripheral pathophysiologic mechanisms (e.g., painful diabetic neuropathy, chemotherapy\u2010induced neuropathy). In this article, we discuss the scientific evidence to target the peripheral cannabinoid system as an alternative to cannabis use for medical purposes, and we review the available literature to determine the pros and cons of potential strategies that can be used to this end.<\/jats:p>","DOI":"10.1002\/phar.1642","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T19:37:56Z","timestamp":1445715476000},"page":"917-925","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Peripherally Restricted Cannabinoids for the Treatment of Pain"],"prefix":"10.1002","volume":"35","author":[{"given":"E. Alfonso","family":"Romero\u2010Sandoval","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Administrative Sciences Presbyterian College School of Pharmacy Clinton South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Asbill","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Administrative Sciences Presbyterian College School of Pharmacy Clinton South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candler A.","family":"Paige","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Administrative Sciences Presbyterian College School of Pharmacy Clinton South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara","family":"Byrd\u2010Glover","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Administrative Sciences Presbyterian College School of Pharmacy Clinton South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1556-4029.2010.01441.x","article-title":"Potency trends of \u03949\u2010THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008","volume":"5","author":"Mehmedic Z","year":"2010","journal-title":"J Forensic Sci"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/phar.1187","article-title":"The pharmacologic and clinical effects of medical cannabis","volume":"2","author":"Borgelt LM","year":"2013","journal-title":"Pharmacotherapy"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.biopsych.2005.01.026","article-title":"Moderation of the effect of adolescent\u2010onset cannabis use on adult psychosis by a functional polymorphism in the catechol\u2010O\u2010methyltransferase gene: longitudinal evidence of a gene X environment interaction","volume":"10","author":"Caspi A","year":"2005","journal-title":"Biol Psychiatry"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/ALN.0b013e318167af74","article-title":"Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury","volume":"4","author":"Romero\u2010Sandoval A","year":"2008","journal-title":"Anesthesiology"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0269881108092393","article-title":"Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users","volume":"3","author":"Ramaekers JG","year":"2009","journal-title":"J Psychopharmacol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mp.2011.82","article-title":"Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers","volume":"6","author":"Hirvonen J","year":"2012","journal-title":"Mol Psychiatry"},{"key":"e_1_2_6_8_1","first-page":"101","volume-title":"Pain Management\u2010 Current Issues and Opinions","author":"Alkaitis MS","year":"2012"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.conb.2013.02.002","article-title":"Molecular mechanisms of cannabinoid addiction","volume":"4","author":"Fratta W","year":"2013","journal-title":"Curr Opin Neurobiol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1460-9568.2004.03645.x","article-title":"Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine","volume":"7","author":"Vigano D","year":"2004","journal-title":"Eur J Neurosci"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biopsych.2004.05.006","article-title":"Adolescent exposure to cannabinoids induces long\u2010lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons","volume":"2","author":"Pistis M","year":"2004","journal-title":"Biol Psychiatry"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2174\/138945010790980312","article-title":"Functional interactions between endogenous cannabinoid and opiod systems: focus on alcohol, genetics, and drug\u2010addicted behaviors","volume":"4","author":"L\u00f3pez\u2010Moreno JA","year":"2010","journal-title":"Curr Drug Targets"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0165-6147(99)01339-5","article-title":"Pharmacological and biochemical interactions between opioids and cannabinoids","volume":"7","author":"Manzanares J","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/pr.109.001933","article-title":"Drug wanting: behavioral sensitization and relapse to drug\u2010seeking behavior","volume":"2","author":"Steketee JD","year":"2011","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1046\/j.1460-9568.2003.02607.x","article-title":"Cannabinoid mechanism in reinstatement of heroin\u2010seeking after a long period of abstinence in rats","volume":"8","author":"Fattore L","year":"2003","journal-title":"Eur J Neurosci"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejphar.2011.04.010","article-title":"The effect of chronic opioid vs. cannabinoid exposure on the expression of tolerance to morphine\u2010 or WIN\u201055,212\u20102\u2010induced analgesia and hypothermia in the guinea pig","volume":"2","author":"Maguma H","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/clpt.2011.188","article-title":"Cannabinoid\u2010opiod interaction in chronic pain","volume":"6","author":"Abrams DICP","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"e_1_2_6_18_1","first-page":"4004","article-title":"Activation of cannabinoid type two receptors (CB) diminish inflammatory responses in macrophages and brain endothelium","volume":"32","author":"Persidsky Y","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1523\/JNEUROSCI.4628-11.2012","article-title":"Activation of cannabinoid receptor 2 attenuates leukocyte\u2010endothelial cell interactions and blood\u2010brain barrier dysfunction under inflammatory conditions","volume":"12","author":"Ramirez SH","year":"2012","journal-title":"J Neurosci"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"13079","DOI":"10.1074\/jbc.M113.536953","article-title":"The endocannabinoid\/endovanilloid N\u2010arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212\u20102 abate the inflammatory activation of human endothelial cells","volume":"19","author":"Wilhelmsen K","year":"2014","journal-title":"J Biol Chem"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2011.11.009","article-title":"Endocannabinoids limit excessive mast cell maturation and activation in human skin","volume":"3","author":"Sugawara K","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/ket447","article-title":"Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis","volume":"5","author":"Gui H","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","article-title":"Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts","volume":"9","author":"Garcia\u2010Gonzalez E","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_6_24_1","first-page":"1115","article-title":"CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve","volume":"12","author":"Sanudo\u2010Pena MC","year":"1999","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2982.2007.00950.x","article-title":"Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity","volume":"9","author":"Hillsley K","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1096\/fj.09-141275","article-title":"Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment","volume":"3","author":"Murikinati S","year":"2010","journal-title":"FASEB J"},{"key":"e_1_2_6_27_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0165-5728(00)00307-6","article-title":"In vivo and in\u00a0vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in\u00a0vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors","volume":"2","author":"Sacerdote P","year":"2000","journal-title":"J Neuroimmunol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.taap.2011.11.005","article-title":"Cannabinoid receptor\u20102 (CB2) agonist ameliorates colitis in IL\u201010(\u2010\/\u2010) mice by attenuating the activation of T cells and promoting their apoptosis","volume":"2","author":"Singh UP","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/bph.12545","article-title":"Anti\u2010inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin\u2010induced uveitis","volume":"6","author":"Toguri JT","year":"2014","journal-title":"Br J Pharmacol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pain.2007.10.024","article-title":"Localization of S100A8 and S100A9 expressing neutrophils to spinal cord during peripheral tissue inflammation","volume":"1","author":"Mitchell K","year":"2008","journal-title":"Pain"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/eji.200737485","article-title":"CNS\u2010infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection\u2010induced neuropathic pain","volume":"2","author":"Cao L","year":"2008","journal-title":"Eur J Immunol"},{"key":"e_1_2_6_32_1","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1073\/pnas.0409888102","article-title":"CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids","volume":"8","author":"Ibrahim MM","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_2_6_33_1","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","article-title":"An efficient randomised, placebo\u2010controlled clinical trial with the irreversible fatty acid amide hydrolase\u20101 inhibitor PF\u201004457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee","volume":"9","author":"Huggins JP","year":"2012","journal-title":"Pain"},{"key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1152\/jn.00692.2014","article-title":"Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy\u2010induced peripheral neuropathy","volume":"5","author":"Uhelski ML","year":"2015","journal-title":"J Neurophysiol"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.phrs.2014.09.008","article-title":"JZL184 is anti\u2010hyperalgesic in a murine model of cisplatin\u2010induced peripheral neuropathy","volume":"90","author":"Khasabova IA","year":"2014","journal-title":"Pharmacol Res"},{"key":"e_1_2_6_36_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuroscience.2014.07.041","article-title":"Activation of CB1 inhibits NGF\u2010induced sensitization of TRPV1 in adult mouse afferent neurons","volume":"277","author":"Wang ZY","year":"2014","journal-title":"Neuroscience"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1152\/jn.90809.2008","article-title":"Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation","volume":"100","author":"Potenzieri CBT","year":"2008","journal-title":"J Neurophysiol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neuropharm.2012.08.009","article-title":"Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin\u2010diabetic rats","volume":"8","author":"Schreiber AK","year":"2012","journal-title":"Neuropharmacology"},{"key":"e_1_2_6_39_1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1476-5381.2010.01192.x","article-title":"Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain","volume":"7","author":"Guindon J","year":"2011","journal-title":"Br J Pharmacol"},{"key":"e_1_2_6_40_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuroscience.2013.05.003","article-title":"The non\u2010selective cannabinoid receptor agonist WIN 55,212\u20102 attenuates responses of C\u2010fiber nociceptors in a murine model of cancer pain","volume":"247","author":"Uhelski ML","year":"2013","journal-title":"Neuroscience"},{"key":"e_1_2_6_41_1","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1021\/jm070317a","article-title":"Naphthalen\u20101\u2010yl\u2010(4\u2010pentyloxynaphthalen\u20101\u2010yl)methanone: a potent, orally bioavailable human CB1\/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration","volume":"16","author":"Dziadulewicz EK","year":"2007","journal-title":"J Med Chem"},{"key":"e_1_2_6_42_1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.lfs.2004.04.010","article-title":"Ajulemic acid: a novel cannabinoid produces analgesia without a \u201chigh.\u201d","volume":"12","author":"Burstein SH","year":"2004","journal-title":"Life Sci"},{"key":"e_1_2_6_43_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1096\/fj.13-239442","article-title":"Control of spasticity in a multiple sclerosis model using central nervous system\u2010excluded CB1 cannabinoid receptor agonists","volume":"1","author":"Pryce G","year":"2014","journal-title":"FASEB J"},{"key":"e_1_2_6_44_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/mol.63.5.983","article-title":"Activation and binding of peroxisome proliferator\u2010activated receptor \u03b3 by synthetic cannabinoid ajulemic acid","volume":"5","author":"Liu J","year":"2003","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_45_1","unstructured":"Adam\u2010WorrallJ HillDR CottneyJ.Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist).2007. Patent WO2007006732 European Patent Office Munich Germany."},{"key":"e_1_2_6_46_1","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.clinthera.2014.10.011","article-title":"Complementary and alternative medical therapies in multiple sclerosis\u2014the American Academy of Neurology guidelines: a commentary","volume":"12","author":"Yadav V","year":"2014","journal-title":"Clin Ther"},{"key":"e_1_2_6_47_1","first-page":"337","article-title":"A peripherally restricted cannabinoid receptor agonist produces robust anti\u2010nociceptive effects in rodent models of inflammatory and neuropathic pain","volume":"2","author":"Yu XH","year":"2010","journal-title":"Pain"},{"key":"e_1_2_6_48_1","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nn.2632","article-title":"Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism","volume":"10","author":"Clapper JR","year":"2010","journal-title":"Nat Neurosci"},{"key":"e_1_2_6_49_1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/jps.20036","article-title":"In vitro\/in\u00a0vivo correlation studies for transdermal delta 8\u2010THC development","volume":"5","author":"Valiveti S","year":"2004","journal-title":"J Pharm Sci"},{"key":"e_1_2_6_50_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0304-3959(02)00401-3","article-title":"Cannabinoid agonists attenuate capsaicin\u2010induced responses in human skin","volume":"3","author":"Rukwied R","year":"2003","journal-title":"Pain"},{"key":"e_1_2_6_51_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2005.09.039","article-title":"Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9\u2010tetrahydrocannabinol","volume":"1","author":"Cichewicz DL","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"e_1_2_6_52_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jconrel.2003.09.001","article-title":"Cannabidiol\u2010 transdermal delivery and anti\u2010inflammatory effect in a murine model","volume":"93","author":"Lodzki MGB","year":"2003","journal-title":"J Controlled Release"},{"key":"e_1_2_6_53_1","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1172\/JCI64628","article-title":"Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes","volume":"9","author":"Olah ABT","year":"2014","journal-title":"J Clin Investig"},{"key":"e_1_2_6_54_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijpharm.2004.03.009","article-title":"Transdermal permation of WIN 55,212\u20102 and CP 55,940 in human skin in\u00a0vitro","volume":"278","author":"Valiveti SKP","year":"2004","journal-title":"Int J Pharm"},{"key":"e_1_2_6_55_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0304-3959(03)00068-X","article-title":"Topical cannabinoid antinociception: synergy with spinal sites","volume":"105","author":"Dogrul AGH","year":"2003","journal-title":"Pain"},{"key":"e_1_2_6_56_1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00000542-200310000-00031","article-title":"Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors","volume":"4","author":"Quartilho A","year":"2003","journal-title":"Anesthesiology"},{"key":"e_1_2_6_57_1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/all.12183","article-title":"Anti\u2010inflammatory activity of topical THC in DNFB\u2010mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors","volume":"8","author":"Gaffal E","year":"2013","journal-title":"Allergy"},{"key":"e_1_2_6_58_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature02282","article-title":"Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1","volume":"6971","author":"Jordt S\u2010E","year":"2004","journal-title":"Nature"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1642","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:32:48Z","timestamp":1761064368000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/phar.1642"],"URL":"https:\/\/doi.org\/10.1002\/phar.1642","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"2015-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}